Pharmaceutical Peptides

Exenatide

Exenatide is a 39-amino acid peptide and GLP-1 receptor agonist originally discovered in the saliva of the Gila monster (Heloderma suspectum). It shares 53% sequence homology with human GLP-1 and is resistant to DPP-4 degradation, providing a longer duration of action than native GLP-1. It was the first GLP-1 receptor agonist approved for type 2 diabetes treatment.

Technical Specifications

Sequence / StructureHis-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Molecular Weight4186.6 g/mol
Purity≥98%
AppearanceWhite lyophilized powder
StorageStore at -20°C, reconstituted at 2-8°C
SolubilitySoluble in water

Application Areas

  • Type 2 diabetes research
  • GLP-1 receptor studies
  • DPP-4 resistance research
  • Appetite regulation
  • Beta-cell preservation
  • Venom-derived peptide research

Published Research on Exenatide

Eng J, Kleinman WA, Singh L, et al. (1992) — Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. DOI: 10.1016/S0021-9258(18)42564-8

DeFronzo RA, Ratner RE, Han J, et al. (2005) — Effects of exenatide on HbA1c and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. DOI: 10.2337/diacare.28.5.1092

Holst JJ. (2007) — The physiology of glucagon-like peptide 1. Physiol Rev. DOI: 10.1152/physrev.00034.2006

Frequently Asked Questions About Exenatide

Exenatide is a 39-amino acid GLP-1 receptor agonist originally derived from Gila monster venom, the first incretin mimetic approved for type 2 diabetes.

Its unique amino acid sequence, particularly the Gly2 position, makes it resistant to dipeptidyl peptidase-4 (DPP-4) cleavage, unlike native GLP-1 which is rapidly degraded.

Our wholesale Exenatide is manufactured to ≥98% purity with full certificates of analysis.

Store lyophilized Exenatide at -20°C. Reconstituted solutions should be kept at 2-8°C.

Exenatide has a shorter half-life than semaglutide or dulaglutide, requiring twice-daily dosing, but remains a valuable research tool as the original incretin mimetic.

Yes, we provide competitive bulk pricing across multiple quantity tiers. Contact our sales team for details.

Related Pharmaceutical Peptides

Request Price List